8月2日晚间，鲁抗医药就上交所关于定增事宜公司的审核问询函发布发布回复（修订稿），就募投项目是否具备产能消化能力、募资规模必要性与合理性、与新华制药是否存在同业竞争等问题做出回答。公告资料显示，早在今年5月9日，鲁抗医药即收到了上交所就公司定增事宜公司发出的审核问询函，此后至今，公司数次发布回复，并根据上交所审核意见，对部分回复内容进行了补充与修订，并披露相关回复（修订稿）。▍募集资金是否投向主业...
Source Link8月2日晚间，鲁抗医药就上交所关于定增事宜公司的审核问询函发布发布回复（修订稿），就募投项目是否具备产能消化能力、募资规模必要性与合理性、与新华制药是否存在同业竞争等问题做出回答。公告资料显示，早在今年5月9日，鲁抗医药即收到了上交所就公司定增事宜公司发出的审核问询函，此后至今，公司数次发布回复，并根据上交所审核意见，对部分回复内容进行了补充与修订，并披露相关回复（修订稿）。▍募集资金是否投向主业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.